Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias. (Q51812877)

13 April 2018

title

Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias. (English)

1 reference

13 April 2018

1 reference

Silvia Maria Díaz Prado

1

1 reference

13 April 2018

José Luis López Cedrún

2

1 reference

13 April 2018

Ramón Luaces Rey

3

1 reference

13 April 2018

Vanessa Medina Villaamil

4

1 reference

13 April 2018

Augusto Alvarez García

5

1 reference

13 April 2018

Manuel Valladares Ayerbes

6

1 reference

13 April 2018

Luis Antón Aparicio

7

1 reference

13 April 2018

publication date

1 July 2010

1 reference

13 April 2018

Experimental and Molecular Pathology

published in

1 reference

13 April 2018

volume

89

1 reference

13 April 2018

page(s)

197-203

1 reference

13 April 2018

issue

2

1 reference

13 April 2018

Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

COX-2 inhibition in upper aerodigestive tract tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Prostaglandin-like material extracted from squamous carcinomas of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Intracellular unesterified arachidonic acid signals apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Many actions of cyclooxygenase-2 in cellular dynamics and in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Wnt signaling controls radiosensitivity via cyclooxygenase-2-mediated Ku expression in head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Targeting cyclooxygenase-2 in human neoplasia: rationale and promise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Regulation of the immune response by prostaglandins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Oral premalignant lesions: is a biopsy reliable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

PCNA and p53 expression in oral leukoplakia with different degrees of keratinization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Oral cancer prevention and the evolution of molecular-targeted drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Advances in chemoprevention of head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Elevated expression of cyclooxygenase-2 in adenocarcinoma of the parotid gland: insights into malignant transformation of pleomorphic adenoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Immunohistochemical localization of epidermal growth factor (EGF) and EGF receptor in human oral mucosa and its malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

The evolution of predictive oncology and molecular-based therapy for oral cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Cyclooxygenase-2 inhibitors in tumorigenesis (part I)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

The mRNA profile of genes in betel quid chewing oral cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Cyclooxygenase-2: a therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Regulation of cyclooxygenase-2 pathway by HER2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Carcinogen substrate specificity of human COX-1 and COX-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Host cyclooxygenase-2 modulates carcinoma growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.06.004

10.1016/J.YEXMP.2010.06.004

7 January 2021

Identifiers

DOI

1 reference

13 April 2018

PubMed ID

20599939

1 reference

13 April 2018